Oral Zinc Sulphate in Treatment of Alopecia Areata (Double Blind; Cross-Over Study)Khalifa E Sharquie1*, Adil A Noaimi1 and Emad R Shwail2
- *Corresponding Author:
- IKhalifa E. Sharquie
Chairman of the Scientific Council of Dermatology & Venereology-Iraqi Board for Medical Specializations. Medical Collection Office
P.O. Box 61080, Postal Code 12114
E-mail: [email protected]
Received date: March 27, 2012; Accepted date: July 18, 2012; Published date: July 23, 2012
Citation:Sharquie KE, Noaimi AA, Shwail ER (2012) Oral Zinc Sulphate in Treatment of Alopecia Areata (Double Blind; Cross-Over Study). J Clin Exp Dermatol Res 3:150. doi: 10.4172/2155-9554.1000150
Copyright: ©2012 Sharquie KE, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: Alopecia areata is a common autoimmune disease that encountered world-wide. Many modalities have been used but no one was universally effective. Zinc sulphate has been used in the treatment of many skin diseases.
Objective: To establish the effectiveness of oral zinc sulphate in the treatment of patchy alopecia areata
Patients and Methods: Patients with alopecia areata who attended the Department of Dermatology-Baghdad Teaching Hospital was recruited into randomized, placebo-controlled, double-blind cross- over trial between February 2008 and September 2009. Patients were randomly allocated to receive either zinc sulphate 5mg /kg/day in three divided doses (Group A) or identical placebo capsules (Group B). Zinc sulphate and placebo capsules were given in
a double-blind manner, following 3 months of starting the treatment, the patients crossed over, i.e. patients on zinc sulphate shifted to placebo and vice versa.
Results: One hundred patients (60 males and 40 females) with patchy AA met the inclusion criteria and enrolled for the study. Sixty-seven patients completed the study, 41(61%) males and 26 (39%) females, their ages ranged from 1.6 - 68 (22.031 ± 14.8505) years. Duration of the disease ranged from 1 - 48 (14.4 ±14.8875) weeks. In group A, at the end of third month, complete hair re-growth with terminal hairs have been obtained in 22 (59.45%) patients. After shifting to placebo treatment the hair continued to grow without relapse and at the end of sixth month, the complete hair re-growth was occurred in 23(62.16%) patients. In group B, at the end of third month, complete hair re-growth had been obtained in 3 (10%) patients. While, after shifting to zinc sulphate the complete hair re-growth obtained in 20 (66.67%) patients. No important side effects were reported apart from mild gastric upset in 8 (11.9%) patients.
Conclusion: Oral zinc sulphate is one of the effective treatment options for AA with low relapse rate after stopping of the treatment.